IN8BIO, INC.

Profile

Company Names

IN8BIO, INC.
INCYSUS THERAPEUTICS, INC.

Addresses

EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY 10118

79 MADISON AVENUE, 2ND FLOOR, NEW YORK, NY 10016

79 MADISON AVENUE, NEW YORK, NY 10016

Phone Numbers

(646) 600-6438
(646) 820-8474

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2018

State Incorporated:

DELAWARE

Total Amount Raised:

$81,904,626.00

Number of Funding Rounds:

4
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
4
2025-12-22 
$20,119,049.00 
$40,239,043.00 
$20,119,994.00 
Equity 
3
2024-10-04 
$12,379,983.00 
$12,379,983.00 
$0.00 
Equity 
2
2023-12-13 
$14,425,013.00 
$14,425,013.00 
$0.00 
Equity 
1
2018-05-07 
$34,980,581.00 
$34,980,581.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
MELISSA 
 
BEELEN 
EXECUTIVE OFFICER
IN8BIO, INC.
PETER 
 
BRANDT 
DIRECTOR
IN8BIO, INC.
THOMAS 
 
CIRRITO 
DIRECTOR
INCYSUS THERAPEUTICS, INC.   |  IN8BIO, INC.
CORINNE 
 
EPPERLY 
DIRECTOR
IN8BIO, INC.
EMILY 
 
FAIRBAIRN 
DIRECTOR
IN8BIO, INC.   |  MOVANO INC.
EMILY 
R. 
FAIRBAIRN 
DIRECTOR
IN8BIO, INC.
TRISHNA 
 
GOSWAMI 
EXECUTIVE OFFICER
IN8BIO, INC.
JEREMY 
 
GRAFF 
DIRECTOR
IMV INC.   |  IN8BIO, INC.
JEREMY 
R. 
GRAFF 
DIRECTOR
IN8BIO, INC.
LUBA 
 
GREENWOOD 
DIRECTOR
KOJIN THERAPEUTICS, INC.   |  IN8BIO, INC.
WILLIAM 
 
HO 
EXECUTIVE OFFICER, DIRECTOR
ALEPHPOINT CAPITAL, LP   |  INCYSUS THERAPEUTICS, INC.   |  RAPT THERAPEUTICS, INC.   |  IN8BIO, INC.
LARRY 
 
LAMB 
EXECUTIVE OFFICER
IN8BIO, INC.
LAWRENCE 
 
LAMB 
EXECUTIVE OFFICER
IN8BIO, INC.
PATRICK 
 
MCCALL 
EXECUTIVE OFFICER
WORLDVU SATELLITES LTD   |  HYPERLOOP TECHNOLOGIES, INC.   |  IN8BIO, INC.
KATE 
 
ROCHLIN 
EXECUTIVE OFFICER
IN8BIO, INC.
ALAN 
S. 
ROEMER 
DIRECTOR
DC BRAU BREWING LLC   |  ENVISAGENICS, INC.   |  IN8BIO, INC.
TRAVIS 
 
WHITFILL 
DIRECTOR
AZITRA INC   |  410 MEDICAL, INC.   |  INCYSUS THERAPEUTICS, INC.   |  IN8BIO, INC.   |  SIRPANT IMMUNOTHERAPEUTICS, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2025-12-30
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2025-12-22 
2024-10-15
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2024-10-04 
2023-12-28
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2023-12-13 
2020-09-04
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2018-05-07 
2018-09-20
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2018-05-07 
2018-05-22
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2018-05-07 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
H.C. WAINWRIGHT + CO., LLC
375
NONE
NONE
NEWBRIDGE SECURITIES CORPORATION
104065
NONE
NONE
CANTOR FITZGERALD + CO.
134